Gilead again backs AlloVir's T cell therapy in $127M direct offering

Gilead and a host of other companies are once again backing T cell immunotherapy biotech AlloVir in a direct offering that will provide the drugmaker with nearly $127 million in proceeds to get its lead therapy to market.